Merck's Strong Second Quarter Driven by Keytruda Sales
Finance

Merck's Strong Second Quarter Driven by Keytruda Sales

authorBy Michele Ferrero
DateAug 04, 2026
Read time2 min

Pharmaceutical giant Merck announced impressive second-quarter financial outcomes, exceeding market forecasts for revenue and elevating its annual earnings outlook. This positive performance was predominantly fueled by the exceptional sales of its flagship cancer immunotherapy, Keytruda.

The U.S. pharmaceutical firm disclosed quarterly earnings of $16.61 billion, marking a 5% increase compared to the previous year and surpassing analysts' average projection of $16.36 billion. While the company recorded a loss for the quarter, this was primarily attributed to a $5.7 billion expense incurred from its acquisition of Terns Pharmaceuticals, a developer of cancer treatments. Excluding this charge, the adjusted loss per share was significantly better than anticipated. Keytruda's sales alone climbed 5% to $8.37 billion, bolstered by the strong adoption of its innovative subcutaneous version, Keytruda QLEX, which outperformed analyst estimates. Furthermore, Gardasil, Merck's HPV vaccine, generated sales slightly above consensus, and animal health product sales also exceeded expectations. However, sales of its measles, mumps, rubella, and chickenpox vaccines experienced a modest decline due to reduced U.S. demand, a trend noted across the broader vaccine market.

Looking ahead, Merck has revised its 2026 revenue forecast upwards, projecting between $66.3 billion and $67.3 billion. The company also anticipates adjusted earnings per share for 2026 to be in the range of $2.66 to $2.76, factoring in acquisition-related expenses. These updated forecasts underscore Merck's optimistic outlook and strategic growth initiatives, particularly in its oncology and vaccine portfolios.

Merck's ability to consistently innovate and deliver life-changing medicines exemplifies the profound impact the pharmaceutical industry has on global health. Their commitment to research and development not only drives economic growth but also offers hope and improved quality of life to countless individuals worldwide, showcasing the essential role of scientific advancement in fostering a healthier and more prosperous future.

More Articles
Finance
Palm Harbour Capital Q2 2026 Investor Letter Excerpt: Portfolio Performance and Market Dynamics
An excerpt from Palm Harbour Capital's Q2 2026 Investor Letter details the firm's portfolio performance, highlighting a 106% upside to estimated NAV and strong financial metrics. Key contributors included Watches of Switzerland, while Vår Energi acted as a detractor. The letter also touches on sector-specific issues like urban broadband competition and the impact of currency fluctuations on Indonesian investments.
By Morgan HouselAug 04, 2026
Finance
Porch Group (PRCH) Analysis: A Promising Investment in Home Technology and Insurance
Porch Group, Inc. (PRCH) stands out as a unique player in the housing and insurance technology sectors. The company's integrated approach, combining property data, industry-specific software, and homeowner services, grants it privileged access to homebuyers and crucial property insights. This strategic positioning establishes a significant competitive advantage by placing PRCH directly within the homeowner's journey. Furthermore, its Insurance Services division effectively converts the growth of Reciprocal's policies into fee and commission revenue, mitigating direct exposure to insurance underwriting risks. With promising growth prospects and an attractive valuation, PRCH presents a compelling "Buy" opportunity for investors.
By Fareed ZakariaAug 04, 2026
Finance
Nextpower's Strategic Evolution: Beyond Solar Trackers
Nextpower is shifting its focus beyond solar trackers to higher-margin, non-tracker products, leveraging its market dominance for platform-based growth. The company boasts strong cash generation and a debt-free balance sheet, justifying its premium valuation. Despite recent market fluctuations, an estimated intrinsic value of $116 per share suggests a compelling entry point, with a 29% potential upside, driven by robust execution and strategic acquisitions. Key risks include U.S. revenue concentration and policy reliance.
By Suze OrmanAug 04, 2026
Finance
Williams to Acquire Momentum Midstream in Major $5.5 Billion Deal
Williams, a leading natural gas company, has announced its acquisition of Momentum Midstream from EnCap Flatrock Midstream for up to $5.5 billion. This strategic move includes a significant cash and debt component along with Williams equity. The transaction, pending regulatory approval, will enhance Williams' footprint in natural gas gathering and transmission, particularly in key Gulf Coast regions, leveraging Momentum Midstream's extensive pipeline network and robust operational capabilities.
By Lisa JingAug 04, 2026
Finance
Meta's Strong First Half of 2026 and AI Investments
Meta demonstrated an exceptional performance in the first half of 2026, with substantial revenue growth. The company's significant investments in AI infrastructure, however, have led to decreased free cash flow, raising questions among investors about the long-term returns and cash generation potential of these strategies.
By Fareed ZakariaAug 04, 2026